{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-059024","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.956746+00:00","generated_at":"2026-06-08T21:28:21.143127+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Candel reports CAN-2409 phase 2 interim data: 71.4% survival at 36 months vs 16.7% in borderline PDAC","bullets":["Estimated overall survival rate 71.4% at 24 & 36 months for CAN-2409 arm vs 16.7% control in borderline resectable PDAC.","Median overall survival not yet reached in CAN-2409 arm; control arm median OS was 12.5 months.","Robust immune activation: dense aggregates of CD8+ granzyme B+ T cells, dendritic cells, and B cells in tumor.","No dose-limiting toxicities or pancreatitis reported; multiple injections generally well tolerated.","5 of 7 CAN-2409 patients alive at data cutoff; two survived >45 months. Control: 1 of 6 alive."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-059024","json":"https://secwatch.observer/filing/0000950170-23-059024.json","markdown":"https://secwatch.observer/filing/0000950170-23-059024.md","text":"https://secwatch.observer/filing/0000950170-23-059024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023059024/0000950170-23-059024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023059024/cadl-20231103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:28:21.143127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}